Abstract Library

#2017 Data on Healthcare Resource Utilization (HCRU) and Treatment Modalities in Patients (Pts) with Advanced (adv), Well-Differentiated (WD) Neuroendocrine Tumors (NETs) of Gastrointestinal (GI) or Lung Origin in Finland

Introduction: The majority of all NETs develop in the GI tract and about one third develop in the lungs; approximately 43% and 51% of pts, respectively, are diagnosed with adv disease (regional or distant metastasis). While GI and lung NETs are rare, their incidence has increased markedly over the past four decades. The severe and progressive nature of adv NET suggests significant costs for pts and payers.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Gaasvik L, Aavikko M, Kurki S, Oddershede L,

Keywords: NET, HCRU, GI, Lung,

#493 Pasireotide and Octreotide LAR Was an Effective Combination in a Patient with Small Intestinal NET with Hypokalemia and a High Level of VIP

Introduction: Small Intestinal neuroendocrine tumors (NET) are argentaffin-positive tumors that progress slowly.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Kozlovacki G, Welin S, Eriksson B, Granberg D, Gaasvik-Blomqvist L,

Keywords: pasireotide, octreotide LAR, small intestinal NET, diarrhea, VIP ,